Evaluation of INR monitoring frequency and time in therapeutic range

Journal of Pharmacy Technology

Volumn 24, Issue 5, 2008, Pages 255-260

  Snyder, Christin M ^a   Helms, Bethany E ^b   Hall, Deanne L ^c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PATIENT MONITORING; RETROSPECTIVE STUDY;

EID: 54849430003     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250802400502     Document Type: Article

References (13)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204-33. DOI 10.1378/chest.126.3_suppl.204S
2. Nichol MB, Knight TK, Dow T, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008;42:62-70. Epub 19 Dec 2007. DOI 10.1345/aph.1K157
3. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol 2003;120:944-7. DOI 10.1309/U7164E0XH5UERKRV
4. Lidstone V, Janes S, Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol 2000;22:291-3.
5. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003;15:213-6.
6. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003;169:293-8.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
8. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISOCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
9. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on outcomes of anticoagulation therapy. Chest 2005;127:1515-22. DOI 10.1378/chest.127.5.1515
10. Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 2006;130:1385-9. DOI 10.1378/chest.130.5. 1385
11. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(suppl 1):S19-24.
12. Rospond RM, Quandt CM, Clark GM, Bussey HI. Evaluation of factors associated with stability of anticoagulation therapy. Pharmacotherapy 1989;9:207-13.
13. Brigden ML, Kay C, Le A, Graydon C, McLeod B. Audit of frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998;59:22-7.